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1. Introduction
Epithelial ovarian cancer causes more deaths than any other cancer of the female reproductive
system and it is the leading cause of death from gynecologic cancer. There is no universally
accepted consensus on the surveillance of ovarian cancer, but if we review the main clinical
guidelines, we can find similar recommendations for follow-up for patients with ovarian
cancer after chemotherapy treatment.
Approximately 60% of patients will experience a relapse after the standard first-line treatment
including cytoreductive surgery and adjuvant chemotherapy [1]. At this time, when relapse
occurs, the chance of cure decreases drastically and treatment is solely palliative. This makes
the increase in overall survival and the quality of life the primary endpoints. Surgery is not
sufficiently validated due to the lack of phase III clinical trials, and there are no approved
targeted therapies in relapsed ovarian cancer. Therefore, chemotherapy is the only option to
achieve these objectives. We will review the role of chemotherapy in recurrent ovarian cancer
in this chapter.
2. Diagnosis of epithelial ovarian cancer relapse
In stages I, II, III and IV complete responders, American guidelines recommend that, after
completing primary surgery and adjuvant chemotherapy, follow-up visits should include a
physical examination with a pelvic exam every 2 to 4 months for the first two years, then every
3 to 6 months until the fifth year, and then annually after the fifth year. Periodic monitoring
of CA 125 and other tumor markers (e.g., CA 19.9, CEA) are also recommended if the markers
were elevated previously. The rest of the examination, which ranges from performing
© 2013 Bermejo et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Computerized Tomography (CT), Magnetic Resonance Imaging (MRI) or Positron Emission
Tomography/Computerized Tomography (PET/CT), will be performed as clinically indicated
such as weight loss, fatigue, bloating, pelvic pain or bowel occlusion [2].
European clinical guidelines recommend a physical exam and routine measurement of CA 125
every 3 months for 2 years, every 4 months during the third year and every 6 months during
years 4 and 5. CT scan will be performed if the CA 125 is elevated or if there is clinical evidence
of relapse [3].
A physical examination to detect recurrent ovarian cancer has limited value and detects
abnormalities that indicate a recurrence only in 3.8 to 4.6% of patients [4, 5]. CT has a sensitivi‐
ty of 40 - 93%, depending on the presence of peritoneal disease, tumor location and the pres‐
ence of ascites. The sensitivity of MRI ranges from 62 to 91%, depending on the location of the
tumor and tumor size. MRI facilitates the detection of disease on the peritoneal and intestinal
surface [6].
We can define the relapse of ovarian cancer with the RECIST (Response Evaluation Criteria in
Solid Tumors) criteria. However, relapse can also be defined as a doubling from the upper
limit of normal value of CA 125 (30 U/mL) in patients who normalized their value after
finishing their treatment, or doubling this value from the nadir (minimum value) in patients
who never had normalized values [7-9]. It is estimated that this rise in the CA 125 level precedes
the clinical detection of recurrence by about three months [10], and this may have implications
at the beginning of the second-line treatment.
3. Classification of relapse
There are several classifications of patients with relapsed ovarian cancer based on the plati‐
num-free interval (Table 1).
Markman suggested that the probability of response in the re-treatment with platinum-based
chemotherapy depends on the platinum-free interval. In a retrospective analysis conducted at
the Memorial Sloan-Kettering Cancer Center (New York, United States of America), these
authors found a subgroup of patients with a higher likelihood of response to platinum salts.
They selected 82 patients who received initial chemotherapeutic treatment with a cisplatin-
based regimen and second-line treatment with a cisplatin- or carboplatin-based regimen, with
a platinum-free interval of more than 4 months. The response rate to second-line treatment in
the three groups according to the platinum-free interval at 5 to 12 months, 13 to 24 months and
more than 24 months, was 27%, 33% and 59%, respectively [11]. They proposed to classify
patients into different groups according to their previous response to platinum-based treat‐
ment and platinum-free interval: primary platinum-resistant (patients who progressed before
the completion of the planned treatment), secondary platinum-resistant (patients who
responded to a platinum regimen and did not respond to a second platinum-based treatment),
and potentially platinum-sensitive (all patients who respond to a platinum-based treatment,
subdivided into patients with platinum-free intervals of less than 6, 6 to 12 months and more
than 12 months) [12].
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In 1993, Thigpen defined two subgroups of patients with relapsed ovarian carcinoma based
on the volume of relapse and the time to relapse after the end of treatment with platinum.
Patients with small-volume disease confined to the peritoneal cavity have a far better chance
of achieving a response to second-line chemotherapy with subsequent prolonged survival than
those with bulky disease or disease outside the abdomen. Thus, we can classify the patients
into those who are still "clinically sensitive" to the platinum-based regimens (initial response
to platinum-based therapy and relapse more than 6 months after cessation of treatment) and
those with "clinically resistant" disease (defined as progression disease during or within 6
months of first-line treatment platinum-based therapy). We should choose a platinum-
containing regimen for relapse for those patients classified as clinically sensitive and an
alternative treatment without platinum salts for those with clinically resistant disease [13].
Until recently, this was the most utilized and simplest classification.
Author Best response to platinum Platinum Free
Interval
Classification
Markman [11,12] Progression ----- Primary Platinum-resistant
No response Any Primary Platinum-resistant
Response < 6 months Potentially platinum-sensitive
Response > 6 months Potentially platinum-sensitive
Thigpen [13] Progression ---- Platinum-resistant
No response Any Platinum-resistant
Response < 6 months Platinum-resistant
Response > 6 months Platinum-sensitive
1998 International
Workshop Consensus
[14]
Progression ---- Platinum-refractory
No response Any Platinum-refractory
Response < 4 months Platinum-refractory
Response > 4 - 12 months Intermediate platinum-sensitive
Response > 12 months Platinum-sensitive
NICE 2005 [15] Progression ---- Platinum-refractory
No response Any Platinum-refractory
2010 GCIG Consensus
[16]
Response < 6 months Platinum-resistant
Response > 6 - 12 months Partially platinum-sensitive
Response > 12 months Platinum-sensitive
Table 1. Classification of relapsed ovarian cancer
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The International Workshop Consensus established a different classification in 1998 and
stratified patients into platinum-refractory (progression during or within 4 months), inter‐
mediate platinum-sensitive (initial response but relapse 4 -12 months) and platinum-sensitive
(relapse after 12 months) [14].
More recently, the National Institute for Health and Clinical Excellence (NICE) in 2005 [15]
and the Gynecologic Cancer InterGroup (GCIG) in 2010 [16] have developed new classifica‐
tions, including partially platinum-sensitive patients (those who relapse between 6 and 12
months after completion of initial platinum-based chemotherapy).
4. Treatment of platinum-sensitive disease
Until the early 2000s, monotherapy with platinum salts was the standard treatment for patients
with platinum-sensitive disease because clinical trials attempting to prove the superiority of
polychemotherapy were negative.
More recent clinical trials have demonstrated the superiority of polychemotherapy versus
monotherapy, making this strategy the standard treatment in patients with platinum-sensitive
disease. We discuss the main previous studies in this section.
4.1. Carboplatin versus carboplatin/paclitaxel (ICON4/AGO-OVAR 2.2)
In parallel, two pragmatic clinical trials were designed to determine whether the combination
of carboplatin and paclitaxel should be used at first relapse after platinum-based chemother‐
apy [the International Collaborative Ovarian Neoplasm 4 (ICON4), coordinated by the
Instituto Mario Negri, Milan, Italy (IRFMN) and the Medical Research Council's Clinical Trials
Unit, London, United Kingdom (MRC CTU), and Arbeitsgemeinschaft Gynaekologische
Onkologie (AGO) OVAR 2.2 coordinated by AGO, Karlsruhe, Germany] [17].
They randomized 802 patients with relapsed epithelial ovarian cancer who previously received
platinum-based chemotherapy and had a platinum-free interval of more than 6 months (more
than 12 months in the ICON4 group) to receive a conventional platinum-based chemotherapy
(the majority of patients (71%) received carboplatin alone) or a combined treatment with
paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin AUC 5 – 6 every 3 weeks for at
least 6 cycles. The primary endpoint was overall survival (OS), and secondary endpoints were
progression-free survival (PFS) and quality of life. The platinum-free interval was greater than
12 months in 75% of patients.
Patients in the AGO protocol must have previously received cisplatin or carboplatin plus
paclitaxel, patients in the MRC CTU protocol trial were permitted to have had more than one
line of previous chemotherapy and patients randomized into the Italian protocol required
measurable disease.
With a median follow-up of 42 months, OS was increased by 5 months (24 versus 29 months),
with an absolute difference in 2-year survival of 7% in favor of paclitaxel plus platinum-based
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chemotherapy (57% versus 50%; Hazard Ratio (HR): 0.82; 95% CI 0.69 - 0.97; p = 0.02). For PFS,
there was a HR: 0.76 (95% CI 0.66 - 0.89; p = 0.0004) in favor of paclitaxel plus platinum-based
chemotherapy, which translates into an absolute difference in median PFS of 3 months in favor
of the combination regimen (9 versus 12 months). The response rate (RR) seemed to be higher
in the combination arm (66%) compared to the conventional chemotherapy arm (p = 0.06).
There were no differences between the quality of life measures in both groups. The results
showed no difference between different subgroups (randomization group, time to relapse,
number of previous lines of chemotherapy, type of prior chemotherapy, age and performance
status).
Paclitaxel plus platinum-based chemotherapy was generally more toxic than conventional
platinum-based chemotherapy, causing more alopecia and neurotoxicity (20% of patients),
while conventional platinum-based chemotherapy was associated with more hematological
toxic effects than paclitaxel plus platinum chemotherapy.
The ICON4/AGO-OVAR 2.2 trial was the first large clinical trial that showed the superiority
of polychemotherapy versus monotherapy in platinum-sensitive ovarian cancer.
Similar results were found in a Spanish randomized phase II clinical trial conducted by GEICO
(Grupo Español de Investigación en Cáncer de Ovario) [18]. In this trial, 81 patients with
platinum-sensitive recurrent ovarian carcinoma were randomized to carboplatin or carbopla‐
tin plus paclitaxel. The primary endpoint was objective response and secondary endpoints
were time to progression, overall survival, tolerability and quality of life. The platinum-free
interval was greater than 12 months in 57.7% of patients. In the intent-to-treat analysis, they
reported a higher response rate in the group treated with carboplatin plus paclitaxel than in
the carboplatin group (75.6% versus 50%; p = 0.017). The median time to progression (49.1
versus 33.7 weeks; p = 0.021) and overall survival (not reached versus 72.7 weeks; p = 0.0021)
were also better in the group treated with the combination therapy. There were no differences
in the quality of life. As in the ICON4/AGO-OVAR 2.2 trial, alopecia (86.8%) and neurotoxicity
(23.7%) were more frequent in patients treated with paclitaxel. Stomatitis (18.4%) and myal‐
gias/arthralgias (36.8%) were also more frequent in this group. In the ICON4/AGO OVAR 2.2
trial, only 40% of patients received paclitaxel as part of a previous treatment, which could affect
the superiority of the paclitaxel arm following the relapse. In the Spanish trial, 87.2% of patients
received paclitaxel previously, so it was suggested that carboplatin plus paclitaxel could be
administered at relapse in patients who received this treatment as first-line therapy.
4.2. Carboplatin versus carboplatin/gemcitabine (AGO-OVAR 2.5)
Neurotoxicity is the main drawback for the re-treatment with carboplatin plus paclitaxel
because, among other factors, co-administration of paclitaxel and platinum compounds can
increase  the  development  of  neurotoxicity  [19].  Neurotoxicity  is  a  cumulative  dose-
dependent toxicity; 715 mg/m2 is the mean cumulative dose to onset of grade 2 or greater
neurotoxicity [20].
In the ICON4-AGO OVAR 2.2 study, moderate or severe neurological effects were observed
in 20% of patients in the combination arm, and the majority of patients experienced grades 1
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to 4 neurotoxicity (75% to 83%) with the combination of carboplatin–paclitaxel and cisplatin-
paclitaxel.
For these reasons, an alternative combination with carboplatin and gemcitabine was designed
to avoid toxic effects, such as neurotoxicity, derived from the combination of carboplatin or
cisplatin and paclitaxel.
In the AGO-OVAR 2.5 [21] clinical trial, the AGO-OVAR investigators, in collaboration with
the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the European
Organization for Research and Treatment of Cancer Gynecological Cancer Group (EORTC
GCG), randomized 356 patients with platinum-sensitive recurrent ovarian cancer to receive
either carboplatin alone (AUC 5) every 21 days or carboplatin AUC 4 on day 1 plus gemcitabine
1000 mg/m2 on days 1 and 8, every 21 days. Patients could receive 6 to 10 cycles in both arms.
The primary objective was progression-free survival, and secondary objectives included the
response rate, duration of response, overall survival, quality of life and toxicity. Both groups
were well balanced: 70.8% of patients had received platinum-based plus taxane as first-line
therapy, and 59.8% of patients had a platinum-free interval greater than 12 months. The study
was not powered to detect differences in OS.
With a median follow-up of 17 months, the median PFS in the combination arm and the
single-agent arm were 8.6 months (95% CI, 7.9 - 9.7) and 5.8 months (95% CI, 5.2 - 7.1),
respectively,  with a 28% reduction in the progression-free event rate (HR: 0.72;  95% CI,
0.58 - 0.90; p = 0.0031). On the other hand, the RR was significantly higher in the gemcita‐
bine plus carboplatin arm than in the carboplatin arm (47.2% versus 30.9%; p = 0.0016).
The HR for overall survival was 0.96 (95% CI, 0.75 - 1.23; p = 0.7349). There was no difference
in OS, which was 18 months for patients treated with carboplatin and gemcitabine versus
17.3 for patients treated with carboplatin alone. Furthermore,  there was no difference in
the quality of life between treatment arms.
A significant increase in serious (grade 3 to 4) hematologic adverse events was documented
in both arms, including neutropenia (71% versus 12%), thrombocytopenia (35% versus 11%)
and anemia (27% versus 8%). These adverse events appeared more commonly in the combi‐
nation arm. The use of granulocyte colony-stimulating factor was more frequent in patients
treated with carboplatin and gemcitabine (24% versus 10%).
The results of the AGO-OVAR 2.5 trial confirmed the superiority of platinum-based polyche‐
motherapy over platinum salts in monotherapy.
The results of this clinical trial provide a treatment alternative to carboplatin/paclitaxel, with
a different profile of toxicity, including less alopecia and neurotoxicity, which can affect the
quality of life for women with ovarian cancer.
4.3. Carboplatin/paclitaxel versus carboplatin/Pegylated Liposomal Doxorubicin (PLD)
(CALYPSO)
In an attempt to establish a new second-line treatment with improved tolerance and equal or
greater efficacy than the standard treatment with carboplatin and paclitaxel, the CALYPSO
clinical trial was designed [22].
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In  this  trial,  a  total  of  976  patients  with  histologically  confirmed  ovarian  cancer  with
recurrence  more  than  6  months  after  first-  or  second-line  platinum-  and  taxane-based
therapies were randomly assigned to receive carboplatin AUC 5 on day 1 plus pegylated
liposomal doxorubicin (PLD) 30 mg/m2 on day 1, every 28 days, or carboplatin AUC 5 on
day 1 plus paclitaxel 175 mg/m2 on day 1 at 3-week intervals for at least 6 cycles (in case
of stabilization of disease or if partial response was achieved after 6 courses, the patients
were allowed to receive therapy until progression). The platinum-free interval was greater
than 12 months in 63.9% of patients.
The study was designed as a non-inferiority trial. The primary endpoint was progression-free
survival, and secondary endpoints were toxicity, quality of life, and overall survival.
With a median follow-up of 22 months, PFS was statistically superior for patients treated with
carboplatin/PLD than patients in the carboplatin/paclitaxel arm (11.3 versus 9.4 months with
HR: 0.821; 95% CI, 0.72 to 0.94; p = 0.005).
Severe  non-hematologic  toxicity  (grades  3  to  4)  was  more  frequent  in  patients  in  the
carboplatin/paclitaxel  arm  than  in  patients  treated  with  carboplatin/PLD  (36.8%  versus
28.4%; p = 0.001). Grade 2 or greater palmar-plantar erythrodisestesia (12% versus 2.2%),
nausea (35.2% versus 24.2%), vomiting (22.5% versus 15.6%) and mucositis (13.9% versus
7%) occurred more commonly in the carboplatin/PLD arm. Grade 2 or greater neurotoxic‐
ity (4.9% versus 26.9%), complete hair loss (7% versus 83.6%) and allergic/hypersensitivi‐
ty reactions (5.6% versus 18.8%) were more frequent in patients treated with carboplatin
and paclitaxel. The allergic/hypersensitivity reactions were mainly secondary to carbopla‐
tin administration and was the reason for significantly lower rates of  early discontinua‐
tion of one or both drugs in the paclitaxel arm compared with the PLD arm (1% versus
6%; p > 0.001). Fewer patients discontinued treatment early for toxicity in the carboplatin/
PLD arm (6% versus 15%; p < 0.001).
Regarding hematologic toxicities, they were generally similar between the treatment groups,
although grades 3 to 4 neutropenia was more frequent in patients treated with carboplatin/
paclitaxel (35.2% versus 45.7%) and grades 3 to 4 thrombocytopenia was more frequent in
patients treated with carboplatin/PLD (15.9% versus 6.2%). There were no differences in febrile
neutropenia or the use of supportive treatment (e.g., transfusion, granulocyte colony-stimu‐
lating factor).
Recently, data on the final OS were reported. With a median follow-up of 49 months, no
statistically significant difference in OS was observed between the two arms (HR: 0.99; 95%
CI: 0.85 - 1.16; p = 0.94). The median OS was 30.7 months in patients treated with carbopla‐
tin  and  PLD and 33.0  months  for  patients  treated  with  carboplatin  and  paclitaxel.  The
authors rationalize this fact with an imbalanced post-study cross-over between arms, with
a greater proportion of patients randomized to carboplatin/paclitaxel receiving post-study
PLD (68%) than patients in the carboplatin/PLD arm receiving post-study paclitaxel (43%;
p < 0.001) [23].
The improved disease-related outcomes achieved with carboplatin/PLD treatment were not
at the expense of quality of life [24].
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This study provides an optional scheme of treatment for patients with platinum-sensitive
ovarian cancer, with a reduction in severe toxicities, including carboplatin hypersensitivity
reactions and peripheral neurotoxicity, both of which can be a reason for limiting the dose.
Carboplatin/PLD also induced far less alopecia, one of the most feared adverse effects of
chemotherapy for the majority of women.
4.4. Carboplatin/gemcitabine versus carboplatin/gemcitabine/bevacizumab (OCEANS)
In ovarian cancer, as in other tumors, the addition of new treatments is required for improved
outcomes.
In a phase III clinical trial, 484 patients with relapsed platinum-sensitive ovarian cancer were
randomly assigned to receive Carboplatin AUC 4 on day 1 and Gemcitabine 1000 mg/m2 on
days 1 and 8, every 21 days with placebo, or bevacizumab 15 mg/kg on day 1, every 21 days
[25]. After 6 to 10 cycles of chemotherapy, bevacizumab or placebo were continued until
toxicity or progression. The primary endpoint was progression-free survival, and secondary
endpoints were overall response rate, overall survival and the duration of response.
With a median follow-up of 24 months, the analysis showed an increase in PFS (12.4 versus
8.4 months with a HR of 0.484; 95% CI 0.388 to 0.605; p < 0.0001) and in the RR (78.5%
versus 57.4%, p < 0.0001) for bevacizumab. The duration of response was also significant‐
ly increased with the addition of bevacizumab (10.4 versus 7.4 months; HR: 0.534; 95% CI:
0.408 - 0.698). With the number of events for the final analysis not yet reached, the OS was
35.2 months in the placebo arm versus 33.3 months in the bevacizumab arm. This could
be related to subsequent therapy, including patients receiving bevacizumab in the place‐
bo arm (31%).
The bevacizumab arm had a higher incidence of grade 3 or higher hypertension (17.4% versus
1%) and proteinuria (8.5% versus < 1%). There was no gastrointestinal perforation in any group.
This is the first positive phase III trial evaluating the addition of a targeting therapy to a
standard platinum-based chemotherapy regimen for recurrent ovarian cancer.
4.5. New perspectives in the treatment of platinum-sensitive disease
The poly (adenosine diphosphate [ADP]-ribose) polymerases (PARPs) are a family of enzymes
that play a role in the repair of DNA damage by repairing base excisions. The tumor-suppressor
proteins BRCA1 and BRCA2 are components of the DNA repair pathway, and it is known that
a germ-line mutation in BRCA1 or BRCA2 is associated with a high risk of the development
of some cancers, including breast, prostate and ovarian cancer. Olaparib (AZD2281) is an oral
PARP inhibitor that has shown activity in cancers associated with BRCA1 or BRCA2 mutations
with an acceptable side-effect profile [26].
A randomized phase II clinical trial was designed to compare the efficacy of olaparib and PLD
in patients with confirmed germ-line BRCA1 or BRCA2 mutations and recurrent or progressed
ovarian cancer within 12 months of the most recent platinum-based chemotherapy regimen
[27]. The primary endpoint was the progression-free survival by RECIST criteria, and secon‐
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dary endpoints included the overall response rate, duration of treatment response, overall
survival, safety and tolerability, and health-related quality of life. Ninety-seven patients were
randomly assigned (1:1:1 ratio) to receive olaparib 200 mg twice per day, 400 mg twice per day
continuously or PLD 50 mg/m2 every 28 days. Patients were stratified by BRCA1 or BRCA2
status and platinum sensitivity (sensitive or resistant). There was no statistically significant
difference in PFS between the olaparib 200 mg, olaparib 400 mg and PLD groups (6.5 months,
8.8 months and 7.1 months, respectively). The overall response rate was 25%, 31% and 18%,
respectively, with no statistically significant difference. A similar duration of response was
also observed (6.0, 6.8 and 5.5 months). There was no difference among groups in the OS or
the health-related quality of life. Nausea, vomiting, fatigue and anemia were the most common
adverse events related to olaparib; the adverse events related to PLD were stomatitis and
palmo-plantar erythrodysesthesia.
In a second randomized phase II study, olaparib was evaluated in the maintenance treatment
for patients with platinum-sensitive relapsed high-grade (grades 2 or 3) ovarian cancer who
responded to their most recent platinum-based chemotherapy [28]. A total of 265 patients were
randomized to receive olaparib 400 mg twice daily or placebo after completion of their last
dose of platinum-based chemotherapy. The primary endpoint was progression-free survival;
it was significantly longer in the olaparib group (8.4 months) than in the placebo group (4.8
months), with a hazard ratio for progression or death of 0.35 (95% CI 0.25 to 0.49; p < 0.001).
Secondary efficacy endpoints were time to progression, objective response rate and overall
survival. The time to progression was also significantly longer in patients treated with olaparib
(8.3 versus 3.7 months; HR: 0.35; 95% CI 0.25 to 0.47; p < 0.001). According to the RECIST
criteria, there was no difference in the response rate (12% versus 4%; p = 0.12) or in the overall
survival in the interim analysis at 38% maturity (29.7 versus 29.9 months; p = 0.75). Nausea,
vomiting, fatigue and anemia were the adverse events, with an incidence of at least 10% or
higher in the olaparib group; the majority of them were grade 1 or 2.
The results of these two trials underline the necessity of further exploring the role of olaparib
and other PARP inhibitors in the treatment of women with recurrent ovarian cancer. It may
well be that their use has to be restricted to BRCA mutated patients, but a better definition of
BRCAness should then be standardized. [29]
5. Treatment of platinum-resistant disease
Patients with platinum-resistant disease have a worse prognosis than patients with platinum-
sensitive disease and a poorer response rate to cytostatic treatment. Although there is no clear
recommendation for the standard treatment in these patients, there is a long list of drugs that
have shown activity in phase II clinical trials in this situation: pegylated liposomal doxorubicin,
topotecan, gemcitabine, paclitaxel, docetaxel, trabectedin, vinorelbine, ifosfamide, etoposide,
and pemetrexed (Table 2).
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Drug Response rate Main toxicity
Pegylated liposomal doxorubicin 20% Hand-foot syndrome, mucositis
Topotecan 6 - 20% Hematologic, alopecia
Gemcitabine 9 - 16% Hematologic
Paclitaxel 13 - 17% Neurotoxicity, alopecia
Docetaxel 23% Hematologic
Trabectedin 6% Hematologic
Vinorelbine 3 - 21% Neutropenia
Ifosfamide 12% Hematologic, central nervous toxicity
Etoposide 27% Neutropenia
Pemetrexed 9 - 21% Neutropenia, asthenia
Table 2. Response rate and toxicity for platinum-resistant disease
The comparisons between some of these drugs in phase III clinical trials do not yield superior
results for any of the drugs in terms of overall or progression-free survival.
As explained, the response rate to platinum compounds is too low in patients with platinum-
resistant disease, so monotherapy with a non-platinum drug is usually preferred because
studies with doublets have not demonstrated superiority in platinum-resistant patients or
either have presented greater toxicity [30 - 37].
Despite its frequent use in clinical practice, endocrine treatment (e.g., Tamoxifen, Letrozole)
is not approved, and there is no good evidence supporting its use. Data on tamoxifen were
obtained from observational studies, not comparative ones, and do not allow us to make any
evidence-based recommendations [38]. In a phase II trial with letrozol carried out in 44 patients
(half of them with platinum-resistant disease) who had primary tumors that expressed the
estrogen receptor, a 9% overall response and 42% stabilization at 12 weeks was obtained in 33
patients with radiologically measurable disease, with a minimal toxicity [39]. In any case, there
are worse data in the literature on the impact of endocrine therapy versus chemotherapy on
progression-free survival [40]. Unfortunately, there are no phase III trials to make any
recommendations about the use of hormone treatment in relapsed ovarian cancer.
The main phase III clinical trials comparing different agents in platinum-resistant relapsed
ovarian cancer are shown below.
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5.1. Topotecan versus paclitaxel
Topotecan and paclitaxel are active in platinum-resistant relapsed ovarian cancer. To compare
the activity of these two drugs in this setting, a phase III clinical trial was conducted in patients
who had progressed during or after platinum-based therapy [41, 42]. A total of 226 patients
were randomized to receive chemotherapy with topotecan 1.5 mg/m2/24 h on 5 consecutive
days, every 21 days (112 patients), or paclitaxel 175 mg/m2, every 21 days (114 patients). The
duration of treatment was dependent on response. Patients with a complete or partial response
continued treatment until progression or for 6 months past the maximal response. Patients
who progressed were removed from the study and patients with stable disease after six courses
were removed from the study or switched to the alternate regimen (the study allowed
crossover of the arms). None of the patients had previously received topotecan or paclitaxel
(not included in standard first-line therapy as of now). Patients were stratified as platinum-
resistant or as early, interim and late relapse groups. In the study, 53% of the patients did not
respond to platinum-based treatment or had progression within 6 months; they had platinum-
resistant disease (55% in the topotecan group and 52% in the paclitaxel group).
The primary efficacy parameters were the response rate, duration of response and time to
progression. The secondary criteria for efficacy were the time to response and survival.
In the whole group of patients in the study, no differences in the response rates (topotecan
20.5% versus paclitaxel 13.2%; p = 0.138) or in the median survival (63 weeks for topotecan
versus 53 weeks for paclitaxel, p = 0.44) were achieved. The duration of response was 32.1
weeks in patients treated with topotecan and 19.7 weeks in patients treated with paclitaxel (p
= 0.222). There was no statistically significant difference in the time to progression after therapy
(18.9 weeks for topotecan versus 14.7 weeks for paclitaxel; p = 0.08). The median time to
documented radiologic response was inferior in the paclitaxel group (6 weeks) than in the
topotecan group (9 weeks; p = 0.041).
Among platinum-resistant patients, the response rates were superior in the topotecan group
than in the paclitaxel group (13.1 versus 6.7%, p = 0.303), and the median overall survival was
28.4 weeks in the topotecan group and 39.7 weeks in patients treated with paclitaxel.
Patients who had no ascites, better performance status and a smaller tumor burden had higher
response rates.
The results of questionnaires on the quality of life, including pain, anorexia, diarrhea, fatigue,
nausea and vomiting, dyspnea, constipation and insomnia, were similar in both groups.
Different toxicities were observed in the two groups. Hematologic toxicity was more frequent
in the topotecan group, including grade 4 neutropenia (79% versus 23% in paclitaxel group; p
< 0.01) and grade 4 thrombocytopenia (25% versus 2% in paclitaxel group; p < 0.01). Other
toxicities more frequent in patients treated with topotecan were fatigue, nausea and vomiting
(generally grades 1 – 2). Patients in the paclitaxel group experienced more alopecia, arthralgia,
myalgia and neurotoxicity.
Patients who received topotecan after paclitaxel in their third-line treatment had an overall
response rate of 13%, compared to 10% (p = 0.638) in patients who received paclitaxel after
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topotecan. The data analysis for those patients receiving the other drug (paclitaxel or topote‐
can) in the third-line therapy showed that there was a degree of non-cross-resistance between
them [43]. Therefore, the use of paclitaxel in first-line therapy does not prevent the adminis‐
tration of topotecan in relapsed epithelial ovarian cancer.
5.2. Paclitaxel versus pegylated liposomal doxorubicin
One study compared PLD 50 mg/m2 every 4 weeks versus paclitaxel 175 mg/m2 every 3 weeks
in 214 patients with relapsed epithelial ovarian cancer [44].
There were no differences in the response rates among patients who received pegylated
liposomal doxorubicin and patients who received paclitaxel (17.8% versus 22.4%; p = 0.034).
There was also no difference in the PFS (21.7 weeks versus 22.4 weeks; p = 0.15) or OS (45.7
weeks versus 56.1 weeks; p = 0.44).
There were no observed differences in the PFS or OS in platinum-resistant or platinum-
sensitive patients.
In the PLD group, hand-foot syndrome, stomatitis, nausea, and vomiting were more frequent.
Conversely, alopecia, myalgia, arthralgia, and paresthesia were more frequent in the paclitaxel
group.
5.3. Pegylated liposomal doxorubicin versus topotecan
To compare the efficacy and safety of PLD and topotecan in relapsed ovarian cancer after
chemotherapy with platinum and taxanes, a phase III clinical trial was carried out in 474
patients [45, 46].
Patients were randomized to receive treatment with PLD 50 mg/m2 every 28 days (239
patients), or topotecan 1.5 mg/m2/24 h on 5 consecutive days, every 21 days (235 patients). The
primary endpoint was time to progression, and the secondary endpoints included overall
survival, response rate, time to response, duration of response and toxicity. The trial included
54% of the platinum-resistant patients in the PLD group and 53% of such patients in the
topotecan group.
There was no difference in the rate of response between the two groups (19.7% in patients
treated with PLD versus 17% in patients treated with topotecan; p = 0.390). A reduction in the
risk of death by 18% was achieved in the group of patients treated with PLD compared to
topotecan (HR = 1.216: 95% CI 1.000 to 1.478, p = 0.050). The median survival was 62.7 weeks
in the PLD group versus 59.7 weeks in the topotecan group.
In the platinum-sensitive population, there were benefits in survival among patients treated
with PLD, with a reduced risk of death by 30% (HR 1.432, 95% CI 1.066 to 1.923, p = 0.017) and
a median survival of 107.9 weeks in the PLD group compared to 70.1 weeks in the topotecan
group. The progression-free survival was 28.9 weeks for the PLD group and 23.3 weeks for
the topotecan group (p =0.037), although the response rate was similar between the two groups
(28.4% in the PLD group versus 28.8% in the topotecan group, p = 0.964).
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In the subgroup of platinum-resistant patients, (54% of the population of the study; 255
patients) there were no statistically significant differences in the response rate (12.3% for PLD
and 6.5% for topotecan, p = 0.118), the PFS (9.1 weeks in patients who received PLD compared
to 13.6 weeks in the topotecan group, p = 0.733), or OS (35.6 weeks for the PLD group and 41.3
for the topotecan group, p = 0.455, with a HR = 1.069, 95% CI 0.823 to 1.387, p = 0.618).
The toxicity profiles of the two drugs were different. The main toxicities in patients treated
with PLD were hand-foot syndrome (49%) and stomatitis (40%). The main toxicities in patients
treated with topotecan were hematological toxicity, so they were more likely to receive
granulocyte colony-stimulating factor (29.1%), erythropoietin (23.1%) and transfusions
(57.8%). Moreover, the toxicity caused by PLD was usually mild to moderate, while the toxicity
caused by topotecan was more severe. Despite this difference, there was no difference in the
health-related quality of life questionnaire at 12 weeks.
5.4. Gemcitabine versus pegylated liposomal doxorubicin
Two randomized phase III trials compared gemcitabine with PLD in patients with platinum-
resistant disease.
The first trial [47] was carried out in 195 patients with platinum-resistant ovarian cancer who
were randomly assigned to receive gemcitabine 1000 mg/m2 on days 1 and 8, every 21 days,
or PLD 50 mg/m2 every 28 days until the progression of disease or unacceptable toxicity. Cross-
over treatment was administered at progression. The primary endpoint was progression-free
survival, and secondary endpoints were response rate, time to treatment failure, survival and
quality of life.
The response rate was similar in both groups (9.2% for gemcitabine versus 11.7% for PLD, p =
0.772). There was no difference in the progression-free survival between patients treated with
gemcitabine and patients treated with PLD (3.6 months versus 3.1 months, p = 0.870). The
overall survival was similar in patients treated with gemcitabine followed by PLD and patients
who received the inverse sequence (12.7 months versus 13.5 months, p = 0.997).
The toxicity profiles were different, with more hand-foot syndrome and stomatitis in the PLD
arm and increased constipation, nausea and vomiting, fatigue and neutropenia in the gemci‐
tabine arm. During the cross-over treatment, toxicity was similar to those observed during the
initial treatment phase.
In a second study [48], 153 patients previously treated with platinum/paclitaxel who had
relapsed or progressed within 12 months (53% within 6 months) were randomized to receive
gemcitabine 1000 mg/m2 on days 1, 8 and 15, every 28 days, or PLD 40 mg/m2 every 28 days.
There were no differences in the response rate (29% for gemcitabine versus 16% for PLD, p =
0.066) or time to progression (20 weeks in gemcitabine group versus 16 weeks in PLD group,
p = 0.411). Although the overall survival was higher in the PLD arm (51 weeks versus 56 weeks,
p = 0.048), this difference was not detected in the platinum-resistant subgroup (relapse or
progression < 6 months). The toxicity profile was similar to the previous study. Health-related
quality of life favored the PLD arm.
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5.5. Canfosfamide versus pegylated liposomal doxorubicin or topotecan
A phase III clinical trial (ASSIST-1) was designed to attempt to demonstrate superiority in
the  overall  survival  (primary  endpoint)  and  progression-free  survival  (secondary  end‐
point)  with  canfosfamide  versus  PLD  or  topotecan  in  patients  who  progressed  despite
second-line  treatment  with  either  topotecan  or  PLD  in  platinum-refractory  or  -resistant
patients [49].
The study included 461 patients randomized to an active control arm (PLD 50 mg/m2 every 28
days or topotecan 1.5 mg/m2 on days 1 – 5, every 21 days, based on the prior therapy) or
canfosfamide 1000 mg/m2 every 21 days.
The median overall survival was 8.5 months with canfosfamide and 13.5 months in the control
arm (p < 0.01). The median OS was similar between PLD and topotecan (14.2 versus 10.8
months; p = 0.1695). The progression-free survival was longer for patients treated in the control
group than for patients in the canfosfamide group (4.3 versus 2.3 months; p < 0.01). Hemato‐
logic adverse events were more frequent in the control arm, and non-hematologic adverse
events were similar in both arms.
6. Extending the platinum-free interval
The cells of ovarian cancer could have intrinsic or acquired resistance to platinum compounds,
which is a large clinical obstacle in the treatment of women with relapsed ovarian cancer. There
are several mechanisms by which tumor cells can develop resistance to platinum, including
increased efflux, enhanced DNA repair of damage caused by chemotherapy and defective cell
death pathways. Some of these mechanisms may be reversible with time. It has been hypothe‐
sized that artificially extending the platinum-free interval with non-cross-resistant chemo‐
therapy may improve the likelihood of responding to platinum salts subsequently
administered and prolong the overall survival [35, 50, 51].
Recently, the OVA-301 trial [35] randomized 672 women with recurrent ovarian cancer to
receive trabectedin 1.1 mg/m2 plus PLD 30 mg/m2 every 21 days, or PLD 50 mg/m2 every 28
days. The primary endpoint was progression-free survival, and secondary endpoints included
overall survival and safety. The PFS was higher in the combination group in the overall
population of the study (7.3 versus 5.8 months; HR = 0.79, p = 0.0190) and in the platinum-
sensitive patients (9.2 versus 7.5 months; HR = 0.73, p = 0.0170). The most common adverse
effects were hand-foot syndrome in the PLD group and neutropenia and a transient ALT
increase in the PLD/trabectedin group. After a median follow-up of 47.4 months, no difference
in overall survival was observed (22.2 months in the combination group versus 18.9 months
in the PLD group; HR = 0.86, p = 0.0835). Despite stratification based on platinum sensitivity,
the authors detected an imbalance in the mean platinum-free interval, which favored the PLD
group (13.3 versus 10.6 months; p = 0.009) [36].
Furthermore, the data reported in patients with a platinum-free interval of 6 - 12 months are
especially interesting. These are the patients who can obtain the most benefit from an extension
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in the platinum-free interval. In this population, the median PFS was 7.4 months in the PLD/
trabectedin group versus 5.5 months in the PLD group (HR = 0.65; p = 0.0152) [52]. The median
OS was 22.4 months in the PLD/trabectedin group versus 16.4 months in the monotherapy arm
(HR = 0.64; p = 0.0027) [36].
In the OVA-301 study, similar proportions of patients received subsequent therapy in each
arm (77% and 76%), with 56% and 57% receiving platinum-based therapies in the 6 - 12 months
subgroup. In this subgroup, the time from randomization to subsequent platinum-based
therapy was significantly longer for patients treated with PLD/trabectedin (9.8 versus 7.9
months; p = 0.0167). Patients randomized to the combination group experienced significantly
longer survival after the initiation of subsequent platinum-based therapy (13.3 versus 9.8
months; HR = 0.63, p = 0.0357) [52]. These data support the hypothesis that the enhanced
survival benefits may be due to an artificial extension of the platinum-free interval. In any case,
this hypothesis should be confirmed in prospective randomized trials.
When the data on patients who received platinum-based therapy as the first subsequent
treatment after PLD/trabectedin or PLD in the 6 - 12 months subset were analyzed, platinum
was delayed 4 months (11.5 versus 7.5 months; HR: 0.61, p = 0.0203) and the overall survival
from the first platinum treatment was significantly extended by a median of 8.7 months (18.6
versus 9.9 months; HR = 0.54, p = 0.0169) [53].
The delay in platinum re-treatment could promote the recovery from toxicities, such as
polyneuropathy or alopecia.
7. Discussion
As previously shown, a longer platinum-free interval is the most important factor associated
with a higher likelihood of response and prolongation of progression-free survival. Therefore,
patients who relapse after six months of completion of chemotherapy and are responders are
candidates for re-treatment with platinum salts.
The considerations in the choice of a second and subsequent line of chemotherapy in recurrent
ovarian cancer may also include assessment of efficacy, cumulative toxicities and the optimal
sequencing of available agents.
Currently, in patients with platinum-sensitive disease, it is preferred to administer a combi‐
nation regimen including a platinum compound and a second active drug (Table 3). The
platinum compound most commonly used is carboplatin, due to its better toxicity profile.
These treatments provide a high response rate and significant improvements in the quality of
life and progression-free survival compared to platinum monotherapy. However, the ideal
platinum combination is unknown, and several regimens are available. Recently, schemes
without platinum, such as PLD/trabectedin, have been developed and can be useful. Never‐
theless, there are no data comparing these regimens to platinum-based schemes, so we must
be prudent.
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Clinical Trial Scheme Patients RR PFS OS
ICON4/AGO-OVAR
2.2 [20] C vs. C/P n = 802 54% vs. 66% 9 vs. 12 m 24 vs. 29 m
AGO-OVAR 2.5 [24] C vs. C/Gem n = 356 30.9 vs. 47.2% 5.8 vs. 8.6 m 18 vs. 17.3 m
CALYPSO [25] C/P vs. C/PLD n = 976 Not achieved 9.4 vs. 11.3 m 33 vs. 30.7 m
OCEANS [28] C/Gem/Pl vs.C/Gem/Bev n = 484
57.4% vs.
78.5% 8.4 vs. 12.4 m 35.2 vs. 33.3 m
Abbreviations: RR: response rate. PFS: progression-free survival. OS: overall survival. C: carboplatin. P: paclitaxel. Gem:
gemcitabine. PLD: pegylated liposomal doxorubicin, m: months.
Table 3. Main phase III clinical trials in platinum-sensitive relapsed ovarian cancer
The ICON4/AGO-OVAR 2.2 trial was the first clinical trial that showed the superiority of
polychemotherapy to monotherapy in patients with platinum-sensitive relapsed ovarian
cancer. The combination of carboplatin and paclitaxel may be used in patients who have no
residual neurotoxicity, especially if the platinum-free interval is greater than one year.
A valid alternative is the administration of carboplatin plus PLD (CALYPSO), which has
demonstrated similar efficacy to carboplatin/paclitaxel and a more favorable toxicity profile,
with less alopecia, neurotoxicity and allergic/hypersensitivity reactions. Perhaps this is the
most commonly used scheme by oncologists worldwide, now conditioned by a globally
limited availability of PLD.
Although no survival benefit was achieved in the AGO-OVAR 2.5 trial with carboplatin and
gemcitabine, the results of this clinical trial allow us to recommend this chemotherapy scheme
as an alternative to carboplatin/paclitaxel, due to its different, and perhaps more favorable,
toxicity profile. This scheme is especially useful for patients with risk factors for neurotoxicity
development. The addition of an anti-angiogenic drug, such as bevacizumab (OCEANS), can
improve outcomes without a significant increase in toxicity.
The incorporation of new active drugs into the treatment of patients with platinum-sensitive
ovarian cancer is also important. Thus, we must be aware of the results of the phase III clinical
trial, HECTOR (ClinicalTrials.gov Identifier: NCT00437307), which compares the combination
of carboplatin plus topotecan with the current standard of care (carboplatin/paclitaxel,
carboplatin/gemcitabine or carboplatin/PLD). The trial may be completed in 2013.
Because the response rate to platinum salts is too low in patients with platinum-resistant
disease, monotherapy with a non-platinum drug is usually the choice in this setting. Compar‐
isons of the efficacy of different active drugs in phase III clinical trials show no superiority of
any of them, and there is no clear recommendation for the standard treatment in these patients.
Therefore, the selection of treatment for platinum-resistant patients will be based on other
criteria, such as toxicity, patient preferences and physician experience. Whenever possible,
patients with platinum-resistant disease should be considered for treatment in clinical trials.
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Recurrent platinum-resistant ovarian cancer has limited treatment options and is generally
treated sequentially with multiple single-agent regimens consisting of non-platinum and non-
taxane chemotherapy.
The most common options are PLD, topotecan and gemcitabine. These options have been
compared in several phase III clinical trials (Table 4), but none of the options have proven
superior. PLD and gemcitabine could be used in patients who do not desire alopecia. Addi‐
tionally, PLD is dosed less frequently than topotecan and gemcitabine, which results in
improved convenience for the patient and a reduction in the use of resources.
Subsequent lines of treatment will be made with available drugs.
Author, year Drugs Patients RR PFS OS
ten Bokkel
Huinink W, 2004
Topotecan vs.
Paclitaxel
n = 226 13.1% vs.
6.7%**
23.1 vs. 14 w* 28.4 vs.
39.7 w**
O'Byrne KJ, 2002 Paclitaxel vs. PLD n = 214 22.4% vs.
17.8%*
22.4 vs. 21.7 w* 56.1 vs.
45.7 w*
Gordon AN, 2004 PLD vs. Topotecan n = 474 12.3% vs.
6.5%**
9.1 vs. 13.6 w** 35.6 vs.
41.3 w**
Mutch DG, 2007 Gemcitabine vs. PLD n = 195 9.2% vs.
11.7%**
3.6 vs. 3.1 m** 12.7 vs.
13.5 m**
Ferrandina G,
2008
Gemcitabine vs. PLD n = 153 29% vs. 16%* 20 vs. 16 w* 51 vs.
56 w*
*Data from the whole group
**Data from platinum-resistant patients
Abbreviations: RR: response rate, PFS: progression-free survival, OS: overall survival, PLD: pegylated liposomal doxoru‐
bicin, w: weeks, m: months.
Table 4. Main phase III clinical trials including platinum-resistant relapsed ovarian cancer
Recently, the use of non-platinum agents in relapsed ovarian cancer to extend the platinum-
free interval has gained interest. The answer to the question of whether the prolongation of
the platinum-free interval increases overall survival after the reintroduction of platinum
should be revealed by two phase III trials currently in progress. The MITO-8 (ClinicalTrials.gov
Identifier: NCT00657878) trial compares carboplatin/paclitaxel followed by PLD versus the
reverse sequence (PLD followed by carboplatin/paclitaxel), and the INOVATYON trial
(ClinicalTrial.gov identifier: NCT01379989) compares the administration of carboplatin/PLD
followed by treatment at the discretion of the investigator versus PLD/trabectedin followed
by a platinum-based.
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